Loading
Oncternal Therapeutics
Oncternal Therapeutics is a San Diego biotech that developed the ROR1 antibody zilovertamab, licensed to Merck as an antibody-drug conjugate, and TK216, a small molecule against the EWS-FLI1 fusion that drives Ewing sarcoma.
Also called: Oncternal Therapeutics, Inc.GTxNASDAQ:ONCT
Overview
Oncternal Therapeutics, formed by the 2019 merger with GTx, developed zilovertamab (cirmtuzumab), a ROR1 antibody studied with ibrutinib in mantle cell lymphoma and chronic lymphocytic leukaemia; the antibody became the basis of Merck's antibody-drug conjugate zilovertamab vedotin. TK216, an inhibitor of the EWS-FLI1 oncoprotein, was tested with vincristine in relapsed Ewing sarcoma. Its later programmes were a ROR1 CAR-T and the androgen receptor antagonist ONCT-534; in 2025 the company discontinued development and moved to wind down.
Headquarters
San Diego, California, US
Scorecard
All companies#427of 1245 companies, score 8
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 1 targets, 2 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:ONCT
Stage
Public
Website
Products
1Phase 2Small-molecule EWS-FLI1 inhibitor
TK216 was an attempt to hit the fusion protein that causes Ewing sarcoma directly, something long thought impossible for a transcription factor. In early trials with vincristine it produced a few responses but not enough to carry the drug forward.
Connected
1drugs
Phase 2Small-molecule EWS-FLI1 inhibitor
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
oncternal.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Link 193 company-less drugs to their makers and add 74 ma… · diff · file
Sourced, not expert-reviewed